Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 52.24 million shares were traded. RXRX stock price reached its highest trading level at $4.64 during the session, while it also had its lowest trading level at $4.18.
Ratios:
For a deeper understanding of Recursion Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.60 and its Current Ratio is at 4.60. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 04 ’25 when Gibson Christopher sold 40,000 shares for $5.21 per share. The transaction valued at 208,400 led to the insider holds 974,229 shares of the business.
Gibson Christopher bought 40,000 shares of RXRX for $208,400 on Nov 04 ’25. On Oct 23 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 100,000 shares for $5.70 each. As a result, the insider received 570,000 and left with 954,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2408233728 and an Enterprise Value of 1830771968. For the stock, the TTM Price-to-Sale (P/S) ratio is 45.88 while its Price-to-Book (P/B) ratio in mrq is 2.17. Its current Enterprise Value per Revenue stands at 41.905 whereas that against EBITDA is -2.858.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.96, which has changed by -0.41071427 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -12.32%, while the 200-Day Moving Average is calculated to be -18.80%.
Shares Statistics:
For the past three months, RXRX has traded an average of 39.71M shares per day and 45407080 over the past ten days. A total of 485.21M shares are outstanding, with a floating share count of 332.88M. Insiders hold about 23.39% of the company’s shares, while institutions hold 57.08% stake in the company. Shares short for RXRX as of 1760486400 were 126348417 with a Short Ratio of 3.18, compared to 1757894400 on 132044177. Therefore, it implies a Short% of Shares Outstanding of 126348417 and a Short% of Float of 31.05.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Recursion Pharmaceuticals Inc (RXRX).The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.32 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.29 and -$1.62 for the fiscal current year, implying an average EPS of -$1.53. EPS for the following year is -$1.2, with 9.0 analysts recommending between -$0.81 and -$1.6.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $21.92M this quarter.It ranges from a high estimate of $37.7M to a low estimate of $16M. As of. The current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $4.55MFor the next quarter, 5 analysts are estimating revenue of $18.55M. There is a high estimate of $21.6M for the next quarter, whereas the lowest estimate is $16M.
A total of 2 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $60M, while the lowest revenue estimate was $56.43M, resulting in an average revenue estimate of $58.21M. In the same quarter a year ago, actual revenue was $58.84MBased on 8 analysts’ estimates, the company’s revenue will be $104.59M in the next fiscal year. The high estimate is $208.4M and the low estimate is $61.1M.
